Introduction
High-dose or "pulse" corticosteroid therapy is used to treat a vast array of conditions. There is considerable evidence for their use in musculoskeletal diseases, such as rheumatoid arthritis, as well as dermatological diseases, such as psoriasis. They are also used in the treatment of a variety of other conditions, including some renal, hematological, ophthalmic, neurological, nephrological, pulmonary, gastrointestinal and neoplastic diseases. Pulse therapy typically refers to the administration of more than 250 mg prednisone (or equivalent) per day in an intermittent fashion to enhance the therapeutic effect and lessen the long-term adverse effects. 1 Although the association between bradycardia and high-dose corticosteroids was first documented in 1986, 2 it is not a commonly reported adverse effect. 1 Cardiac arrhythmias have been reported to occur in 1% to 82% of patients receiving high doses of corticosteroids. 3, 4 These adverse effects, which include atrial fibrillation/flutter, ventricular tachycardias and sinus bradycardia, 5 are usually associated with the intravenous route of administration. New reports have emerged, however, indicating that oral pulse steroids have a similar risk of inducing bradycardia and other arrhythmias. [5] [6] [7] This is of significance because the oral route of administration is becoming increasingly more common due to the improved patient convenience and cost and similar efficacy. 1 In this report, we describe a patient who developed bradycardia after receiving a course of oral corticosteroids for the treatment of a multiple sclerosis exacerbation. We hope that this case serves as a reminder of the critical role that pharmacists can play in preventing and monitoring for corticosteroid-induced bradycardia.
Description of case
A 39-year-old woman (height, 170 cm; weight, 124.3 kg) presented to the emergency department with a 3-day history of a slow heart rate and slight chest pressure. On examination, her blood pressure was 124/73 mmHg, and her heart rate was 38 beats per minute. Electrolytes at the time of admission were within the normal range: sodium (141 mmol/L), potassium (3.7 mmol/L) and chloride (109 mmol/L). Other relevant blood work included creatinine (71 µmol/L), creatinine kinase (74 U/L), troponin I (0.003 µg/L) and random glucose (7.5 mmol/L). An electrocardiogram was ordered and confirmed a diagnosis of sinus bradycardia.
Medications at the time of admission included fluticasone/salmeterol 250/25 mcg inhaler daily, montelukast sodium 10 mg once daily, medroxyprogesterone acetate injectable suspension 150 mg/mL every 3 months, levothyroxine 125 µg once daily and zopiclone 7.5 mg at bedtime when needed. Over-the-counter supplements included vitamin D 3 , vitamin C and glucosamine. The patient's medical history included asthma and hypothyroidism, which were both well controlled. A recent diagnosis of multiple sclerosis and symptoms of fatigue, left-sided numbness and prominent nocturia had prompted the initiation of a short course of oral pulse steroids. Prednisone 1250 mg daily for 5 days was prescribed beginning 5 days prior to presenting to the emergency department.
The patient's medical history was negative for any type of cardiovascular disease, and she CASE REPORT did not have any allergies that would suggest an anaphylactoid reaction. In the absence of other medical conditions or medication changes that could account for her erratic fluctuations in heart rate, it was concluded that the patient had experienced an episode of corticosteroidinduced bradycardia. Using the Adverse Drug Reaction Probability (Naranjo) Scale, which is used to help assess and determine the causality for adverse drug reactions, 8 a score of 7 was calculated for our patient's reaction, which indicates a probable causal association.
The patient was admitted to the hospital and given acetylsalicylic acid 160 mg orally. Her cardiac status was monitored by telemetry until the episode of bradycardia resolved. Over the next 24 hours, her heart rate fluctuated between 35 and 160 beats per minute. No further prednisone was given in the hospital, and the patient denied any other history of oral corticosteroid usage.
Discussion
A systematic literature review was conducted to identify publications describing the association between bradycardia and the use of corticosteroids. The search terms "bradycardia" and "corticosteroids" were entered into MEDLINE, EMBASE, Scopus and International Pharmaceutical Abstracts (for the dates 1970-2014). In total, 6 case reports, 4 case series and 3 studies (1 retrospective and 2 prospective) were identified, which cumulatively involved 165 patients and a total of 93 cases of bradycardia attributed to the administration of pulse steroids (Table 1) . One case report was excluded because the report was in Spanish and translation was not possible. 9 Corticosteroids have been used in the management of inflammatory diseases for the past 50 years, but due to variations in dosing, duration and routes of administration, there is little clarity on all potential adverse effects. 1 The adverse effects most commonly noted with intravenous pulse therapy include hypertension, hyperglycemia, hypokalemia, behavioural changes and infections. The most serious adverse effects reported in the literature include arrhythmias and sudden death. 10 This literature review indicated a consensus that corticosteroids can also play a role in inducing bradycardia in a small portion of patients; incidents have been noted in both adults and children. Although the majority of the reports involved high-dose intravenous corticosteroids, 3 case reports described the occurrence of bradycardia after the oral route of administration. 6, 7, 15 Prednisone was the corticosteroid involved in 2 of these cases, while methylprednisolone was implicated in the other. Intravenous methylprednisolone and intravenous dexamethasone were identified 2,5-7,11-18 as the causative agents in all of the other publications.
The patients in these reports presented with both symptomatic and asymptomatic bradycardia, with asymptomatic occurring more frequently. Individuals with symptoms usually experienced dizziness and chest pressure/pain. 7, 19 There was no difference in how symptomatic or asymptomatic bradycardia was managed. Both were transient and resolved without medical intervention after 3 to 10 days. In some cases, the corticosteroid was stopped or the dose reduced. 6, 11, 16 Consistent with the literature, our patient experienced complete resolution of her symptoms without any interventions. [5] [6] [7] 18 The exact etiology of steroid-induced bradycardia is unknown, but several mechanisms have been proposed. Animal studies have demonstrated that high-dose methylprednisolone has significant cardiac effects that may be mediated by direct action on the myocardial membrane and via alterations in cardiovascular sensitivity to catecholamines. 5 In humans, corticosteroids may have the ability to induce sudden electrolyte shifts, resulting in cardiac arrhythmias including bradycardia. 10 Another proposed mechanism is that pulse corticosteroids induce changes in sodium and water physiology, which result in the expansion of plasma volume and in turn activate low-pressure baroreceptors. 5 Regardless, it is likely that corticosteroid-induced bradycardia has a multifactorial cause.
Many factors can contribute to the development of bradycardia after a pulse of corticosteroid therapy. These predisposing factors include rapid rates of intravenous corticosteroid infusion (typically under 30 minutes) and underlying cardiac disease or renal disease. 12, 20 In the absence of an underlying cardiac or renal disease, corticosteroid bradycardia seems to be well tolerated and benign. 5, 6, 20 Pharmacists should pay particular attention to high-risk individuals and monitor them closely. Electrolytes, especially potassium, should be monitored before treatment and deficits corrected if present. 1 Monitoring the patient's heart rate and telemetry may be indicated and should be considered for certain high-risk individuals. 17, 21 In our case, the patient presented to the emergency department with (continued) CASE REPORT bradycardia 5 days after the initiation of her oral pulse corticosteroid therapy. The delay in onset, ranging from 1 to 7 days, was a common finding among some of the reports. 2, 5, 6 This late onset can make it difficult to identify corticosteroids as the cause. As described by Gardiner and Griffith, 22 bradycardia can take up to 6 days after the administration of pulse corticosteroids to become apparent. They noted that this "silent" bradycardia could be present for many of the sudden deaths associated with pulsed corticosteroids. 10, 22 The limitations of this review should be mentioned. Our review included case reports and studies regarding bradycardia associated with corticosteroids; however, we did not include literature pertaining to sudden death because we could not be certain that the direct cause was bradycardia. While several reports were identified specifically relating to bradycardia, overall, the level of evidence was of low quality, with case reports and case series considered as level 3 evidence. Only 3 actual studies on this topic could be identified, and of them, only 1 was a prospective controlled study, which could be classified as level 2 evidence.
Nevertheless, based on the reviewed literature, we believe that pharmacists can play a key role in the prevention and monitoring of corticosteroidinduced bradycardia. Because corticosteroidinduced bradycardia has been associated with rapid infusion rates, pharmacists working in the hospital setting should intervene on orders written for infusion rates of less than 30 minutes. Patients with an underlying cardiac or renal disease are considered at high risk for developing bradycardia, and pharmacists should recommend potassium monitoring and correction prior to treatment and heart rate monitoring for these individuals. Telemetry may also be suggested in certain situations, particularly for those with compromised cardiovascular mechanics. Pharmacists should counsel patients receiving pulse steroids about the potential for bradycardia and teach them how to monitor their pulse. Patients who experience symptoms of chest pressure, pain, shortness of breath or a heart rate of less than 50 beats per minute should be advised to seek immediate medical attention.
Conclusion
Pulse corticosteroid therapies are used frequently in the treatment of many diseases, including multiple sclerosis and rheumatoid arthritis. 16, 19 We hope that this case serves as a reminder that pulse steroids carry different adverse effects than long-term corticosteroid therapy 1 and that bradycardia can occur with even the oral route of administration. Pharmacists should be cognizant that patients receiving large doses of corticosteroids, even for a short time, may experience adverse effects such as bradycardia. Pharmacists practising in both hospital and community settings have the opportunity to provide education and monitoring for this rare but potentially serious adverse effect. ■ From the College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan. Contact holly.mansell@usask.ca.
